Liver cirrhosis patients: new drug may cut rebleeding risk
NCT ID NCT07352228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether carvedilol, a newer blood pressure drug, works better than the standard drug propranolol for preventing another bleeding episode in people with liver cirrhosis who have already had variceal bleeding. Both drugs are given alongside a procedure to tie off swollen veins. The trial will enroll 350 adults aged 18-75 and follow them for up to 3 years to compare rebleeding rates and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARVEDILOL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Air Force Medical University
Xi'an, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common heart drug boost cancer treatment? a trial puts propranolol to the test
- Could a common supplement help liver patients in intensive care?
- New blood thinner trial aims to prevent rebleeding in liver patients
- Ultrasound may replace scopes for bleeding risk in liver patients
- Common heartburn meds may raise risks for liver patients, new study warns
- New Fiber-Optic tech aims to make liver shunt surgery safer